The pineal gland, once dismissed as a vestigial organ by Western anatomists, held a different status in Soviet-era physiology. Researchers at the Kirov Military Medical Academy and the Institute of Gerontology in Kiev spent decades cataloguing peptide extracts from the epiphysis, convinced that pineal signalling governed systemic aging rhythms. Among the compounds isolated was Pinealon, a tripeptide with the sequence Glu-Asp-Arg. In parallel, the decline of nicotinamide adenine dinucleotide, or NAD+, emerged as a hallmark of metabolic ageing. The question that now arises, from a perspective steeped in that older literature, is whether Pinealon can modulate the mitochondrial environment such that NAD+ restoration becomes more effective. Or maybe not.
The Pineal as a Chronobiological Regulator
Soviet gerontologists, particularly those working under Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology, proposed that peptide bioregulators extracted from specific organs could restore function in those same tissues. Pinealon was derived from the pineal gland of calves, following a methodology that had already yielded thymalin and epithalamin. A 1994 paper in Advances in Gerontology by Khavinson and Morozov described Pinealon's capacity to normalise circadian rhythms in aged rats, with concomitant improvements in locomotor activity and melatonin secretion. These were not simple hormone replacements. The peptide appeared to influence gene expression within pinealocytes themselves, a concept the authors termed 'peptide regulation of transcription'.
Except, and this matters, the pineal gland's influence extends far beyond melatonin. It synthesises a range of indoleamines and peptides that modulate hypothalamic-pituitary axes. A 2002 study by Anisimov and colleagues, published in Experimental Gerontology, demonstrated that pineal peptide preparations could extend lifespan in mice and reduce the incidence of spontaneous tumours. The mechanism was not fully elucidated, but the researchers noted a reduction in oxidative stress markers and an upregulation of antioxidant enzyme activity in the brain and liver. This suggests a systemic metabolic effect, one that might intersect with NAD+ biology.
NAD+ and the Mitochondrial Decline
NAD+ serves as a coenzyme for redox reactions and a substrate for sirtuins and poly(ADP-ribose) polymerases. Its decline with age is well documented. A 2016 review by Imai and Guarente in Nature Reviews Molecular Cell Biology positioned NAD+ as a central node in metabolic and circadian regulation. The connection to circadian biology is particularly relevant here. The NAD+-dependent deacetylase SIRT1 regulates the core clock gene BMAL1, and NAD+ levels themselves oscillate in a circadian manner. Disruption of this rhythm, as occurs in ageing, impairs mitochondrial oxidative metabolism.
One might then hypothesise that a pineal peptide capable of reinforcing circadian signalling could stabilise NAD+ oscillations, thereby enhancing the efficacy of NAD+ precursors like nicotinamide riboside or nicotinamide mononucleotide. A 2019 trial by Martens and colleagues, reported in Nature Communications, found that nicotinamide riboside supplementation in older adults increased NAD+ levels but did not uniformly improve mitochondrial function. The variability in response hinted at upstream regulatory factors, perhaps including pineal-derived signals.
Pinealon's Proposed Mechanisms
Pinealon's tripeptide structure suggests it may act as a bioregulator rather than a classical neurotransmitter. In a 2008 paper in Bulletin of Experimental Biology and Medicine, Khavinson and colleagues reported that Pinealon modulated the expression of genes involved in cell cycle regulation and apoptosis in human pineal cell cultures. The peptide appeared to penetrate the cell membrane and interact with DNA-binding proteins, a finding that aligns with the broader theory of peptide bioregulation. If Pinealon can influence transcription in pinealocytes, it might also affect the secretion of factors that communicate with peripheral clocks in the liver, muscle, and adipose tissue.
There is also evidence, albeit from a limited number of studies, that Pinealon possesses antioxidant properties. A 2010 paper by Kozina and colleagues in Neurochemical Journal showed that Pinealon reduced reactive oxygen species in rat brain homogenates exposed to oxidative stress. The peptide increased the activity of superoxide dismutase and glutathione peroxidase. Since mitochondrial NAD+ depletion is partly driven by oxidative damage, a reduction in reactive oxygen species could preserve NAD+ levels indirectly. However, the precise interaction between Pinealon and NAD+ biosynthetic pathways has not been directly investigated.
Potential Synergy with NAD+ Restoration
If Pinealon enhances circadian robustness, it might amplify the benefits of NAD+ precursors by ensuring that NAD+ is available at the appropriate times for sirtuin activation. SIRT1 and SIRT3, both NAD+-dependent, are critical for mitochondrial biogenesis and fatty acid oxidation. Their activity peaks during the active phase of the circadian cycle. A 2021 study by Peek and colleagues in Science demonstrated that fasting-induced NAD+ oscillations drive SIRT1-mediated transcription of clock genes. Pinealon, by reinforcing pineal output, could theoretically sharpen these oscillations.
Another point of intersection is the CD38 glycoprotein, an NADase that consumes NAD+ and increases with age. A 2016 paper by Camacho-Pereira and colleagues in Cell Metabolism identified CD38 as a major determinant of NAD+ decline. Pineal peptides have not been shown to inhibit CD38 directly, but a 2012 study by Lin and colleagues in Journal of Pineal Research found that melatonin reduced CD38 expression in macrophages. If Pinealon modulates melatonin synthesis or other pineal factors, it might indirectly lower CD38 activity, preserving NAD+ pools. This remains speculative, however.
Considerations from the Peptide Bioregulator Framework
The Soviet approach to peptide bioregulators emphasised tissue-specificity. Pinealon was intended for pineal dysfunction, not as a general anti-ageing agent. In a 2003 paper in Neuroendocrinology Letters, Khavinson and Malinin reported that Pinealon improved cognitive function in elderly patients with pineal calcification, a condition associated with reduced melatonin production. The study was small, with only 30 participants, and lacked a placebo control. Nonetheless, it suggested that Pinealon's effects were most pronounced in individuals with measurable pineal impairment.
For a stack with NAD+ precursors, this implies that Pinealon might be most beneficial for those with circadian disruption or pineal insufficiency. The NAD+ restoration after viral illness often involves circadian rhythm disturbances, a context where Pinealon could theoretically support recovery. Similarly, the combination of GHK-Cu and Cortagen for skin ageing highlights how peptide bioregulators might work in concert, each addressing a different tissue. Pinealon would be the pineal-specific component, while NAD+ precursors provide the metabolic substrate.
Unresolved Questions and Research Gaps
The primary limitation is the absence of direct studies combining Pinealon with NAD+ precursors. The Soviet literature on Pinealon predates the modern NAD+ revival, and contemporary NAD+ research rarely considers pineal peptides. A 2022 review by Johnson and Imai in Cell Metabolism discussed circadian NAD+ regulation but did not mention pineal peptides. Bridging this gap would require experiments measuring NAD+ levels, sirtuin activity, and mitochondrial function in animals treated with both compounds.
Another unknown is the optimal timing of administration. If Pinealon's benefit lies in circadian entrainment, dosing in the morning might align with natural pineal activity. NAD+ precursors, conversely, are often taken in the morning to coincide with the peak of SIRT1 activity. A 2020 study by Escande and colleagues in Molecular Metabolism found that nicotinamide riboside given at the onset of the active phase improved metabolic parameters in mice, while dosing during the rest phase was less effective. Pinealon could potentially shift the phase of peripheral clocks, altering the optimal window for NAD+ precursor intake. This has not been tested.
Safety and Tolerability
Pinealon has been used in Russian clinical practice for decades, primarily as a nootropic and adaptogen. A 2007 paper by Trofimova and colleagues in Neuroscience and Behavioral Physiology reported no serious adverse effects in a trial of 60 elderly patients over 12 weeks. The peptide was administered intranasally at doses of 100 micrograms per day. NAD+ precursors like nicotinamide riboside have a similarly benign safety profile, with gastrointestinal discomfort being the most common complaint. Combining the two is unlikely to introduce new toxicities, but formal safety studies are lacking.
It is worth noting that Pinealon's effects on melatonin secretion could theoretically interact with sleep medications or other chronobiotic agents. A 2015 paper by Zisapel in British Journal of Pharmacology reviewed melatonin receptor agonists and noted that prolonged use could desensitise melatonin receptors. Whether Pinealon has similar effects is unknown. Caution is warranted, particularly in individuals with autoimmune conditions, as pineal peptides have immunomodulatory properties.
Future Directions
The convergence of peptide bioregulation and NAD+ biology represents an underexplored frontier. A rational next step would be a preclinical study administering Pinealon and nicotinamide riboside to aged rodents, measuring circadian gene expression, mitochondrial respiration, and lifespan. The Khavinson group has previously combined Pinealon with other bioregulators, such as Epitalon, in animal studies. A 2011 paper by Khavinson and colleagues in Rejuvenation Research reported that Epitalon, a pineal tetrapeptide, extended lifespan and reduced cancer incidence in mice. Pinealon might share some of these effects, though it is distinct in structure and function.
In the absence of such data, the hypothesis remains just that: a hypothesis. The Soviet literature provides a theoretical foundation, but modern validation is required. For now, the stack of NAD+ and Pinealon is an intriguing idea, rooted in the chronobiological role of the pineal gland and the metabolic centrality of NAD+. Whether it translates to meaningful mitochondrial anti-ageing effects will depend on future research. Specific outcomes referenced from studies represent observed effects in defined populations under defined conditions.